The RTP manufacturing facility will support the company's clinical studies and early commercial launch in North America and Europe
The facility will manufacture its Herceptin biosimilar, Tuznue
The COVID-19 pandemic has triggered the rapid growth of the biotherapeutics market
The sale is expected to close in the first quarter of 2022
Heterologous booster vaccination refers to the use of vaccine boosters from different technology platforms from the prime vaccines, which could improve the overall immune response and enhance protection against other variants
Dr. Reddy’s, will focus its resources and capabilities on its key therapy spaces of gastroenterology, pain management, cold and flu, allergy, oncology, neurology, paediatrics and women’s health as the Russia and CIS region continues to be a strong performer for the company
CEPI is accelerating its programme to develop broadly protective coronavirus vaccines—a core part of US $ 3.5 billion pandemic preparedness plan
The partnership is already underway having launched earlier last week, and the contract could be worth up to £211 million.
The newly enhanced drug development platform will help empower innovators with the fastest development timelines
Subscribe To Our Newsletter & Stay Updated